NRX Pharmaceuticals Inc. (NASDAQ: NRXP) and its wholly-owned subsidiary, HOPE Therapeutics, Inc., have announced the signing of a definitive agreement to acquire the Kadima Neuropsychiatry Institute, located in La Jolla, CA. This acquisition is set to form the foundation for the HOPE Network of Interventional Psychiatry Clinics. Kadima, renowned for its pioneering work in CNS and psychedelic research, will serve as the clinical model for HOPE's treatment offerings across the nation. Dr. David Feifel, a distinguished figure in interventional psychiatry, will join HOPE as the Chief Medical Innovation Officer following the acquisition's closure. The transaction, expected to enhance revenue and EBITDA for both NRx and HOPE, is subject to standard closing conditions and finalization of financing. Further details will be disclosed in due course.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.